tiprankstipranks
Trending News
More News >
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
Advertisement

Phio Pharmaceuticals (PHIO) AI Stock Analysis

Compare
578 Followers

Top Page

PHIO

Phio Pharmaceuticals

(NASDAQ:PHIO)

Rating:42Neutral
Price Target:
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
Positive Factors
Clinical Trials
The safety monitoring committee recommends advancing PH-762 to final cohorts, indicating a clean safety profile and potential for first in class product status.
Market Potential
The stock is considered undervalued with significant potential upside, driven by PH-762's promising trial results and the company's strategic positioning.
Strategic Positioning
Phio Pharmaceuticals maintains business development optionality as it advances its portfolio of conditionally active siRNA therapies, positioning itself well for potential partnerships.
Negative Factors
Clinical Risks
Factors that could impede reaching the price target include failed or inconclusive clinical trials and the inability to secure adequate funding.
Market Competition
Despite the crowded skin cancer therapy market, there is a high unmet need due to the tumor's high incidence, less than optimal efficacy of available treatment options, and drug resistance to systemic therapies.

Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)

Phio Pharmaceuticals Business Overview & Revenue Model

Company DescriptionPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
How the Company Makes MoneyPhio Pharmaceuticals generates revenue through strategic partnerships, research collaborations, and licensing agreements related to its RNAi technology platform. The company aims to out-license its proprietary sd-rxRNA technology to larger pharmaceutical or biotechnology companies, which can incorporate these therapies into their own cancer treatment pipelines. Additionally, Phio may receive milestone payments and royalties from these partnerships based on the successful development and commercialization of its therapeutics. The company might also secure funding through grants and government programs aimed at supporting innovative cancer research.

Phio Pharmaceuticals Financial Statement Overview

Summary
Phio Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing operational losses. The balance sheet shows low leverage, but the cash flow situation is concerning due to consistent cash burn and a reliance on external financing. The company must focus on revenue generation and efficient cash management to improve its financial health.
Income Statement
10
Very Negative
Phio Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of product commercialization. The net income remains negative, reflecting persistent losses. The company's inability to generate revenue and its ongoing operational losses are significant concerns.
Balance Sheet
40
Negative
The company maintains a strong equity position relative to its assets, with a high equity ratio indicating minimal leverage. However, the substantial cash burn and diminishing cash reserves are potential risks if new funding is not secured.
Cash Flow
30
Negative
Operating cash flow remains negative, indicative of ongoing operational challenges. While the company has managed to secure financing to cover cash flow needs, the absence of free cash flow growth poses a risk to long-term sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue70.00K0.000.000.000.000.00
Gross Profit-609.00K-35.00K-6.33M-193.00K-192.00K-183.00K
EBITDA-7.34M-7.12M-10.64M-11.29M-13.09M-8.72M
Net Income-7.08M-7.15M-10.83M-11.30M-13.21M-8.79M
Balance Sheet
Total Assets11.30M5.74M9.36M12.81M25.17M15.74M
Cash, Cash Equivalents and Short-Term Investments10.78M5.38M8.49M11.78M24.06M14.24M
Total Debt0.000.0035.00K305.00K295.00K642.00K
Total Liabilities1.21M1.01M1.63M1.98M3.24M2.72M
Stockholders Equity10.10M4.72M7.73M10.84M21.93M13.02M
Cash Flow
Free Cash Flow-6.55M-7.11M-10.75M-12.25M-11.91M-8.82M
Operating Cash Flow-6.55M-7.11M-10.75M-12.13M-11.86M-8.80M
Investing Cash Flow3.00K8.00K-5.00K-121.00K-51.00K-19.00K
Financing Cash Flow13.21M4.00M7.41M-26.00K21.72M16.13M

Phio Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.07
Price Trends
50DMA
2.35
Negative
100DMA
2.14
Negative
200DMA
2.14
Negative
Market Momentum
MACD
-0.09
Positive
RSI
37.73
Neutral
STOCH
25.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Negative. The current price of 2.07 is below the 20-day moving average (MA) of 2.28, below the 50-day MA of 2.35, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 37.73 is Neutral, neither overbought nor oversold. The STOCH value of 25.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHIO.

Phio Pharmaceuticals Risk Analysis

Phio Pharmaceuticals disclosed 26 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Phio Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.77B-0.12-39.78%2.21%22.68%-1.42%
48
Neutral
$12.01M-137.09%247.62%-7.66%
42
Neutral
$11.89M-90.83%650.00%85.42%
42
Neutral
$11.51M-102.18%85.26%
41
Neutral
$11.07M-655.00%-26.38%40.99%
28
Underperform
$13.83M-169.59%85.35%
$15.87M-213.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PHIO
Phio Pharmaceuticals
2.07
-1.18
-36.31%
IBIO
Ibio
0.78
-1.25
-61.58%
EVGN
Evogene
1.28
-2.60
-67.01%
WINT
Windtree Therapeutics
0.14
-532.36
-99.97%
BRTX
BioRestorative Therapies
1.51
-0.19
-11.18%
LIXT
Lixte Biotechnology Holdings
3.41
1.61
89.44%

Phio Pharmaceuticals Corporate Events

Executive/Board Changes
Phio Pharmaceuticals Appoints David Deming to Board
Positive
Feb 20, 2025

Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025